UnitedHealth Q3 2026: an 88.4% care ratio with $610M of reserve help

UnitedHealth Group is two businesses under one roof: UnitedHealthcare, which provides health benefits to employers, individuals and government-program beneficiaries, and Optum, which delivers care (Optum Health), sells data, analytics and technology to the health system (Optum Insight) and runs pharmacy services (Optum Rx). In the quarter ended September 30 the combined company booked $112.7 billion of revenue, $6.6 billion of earnings from operations, $4.56 of GAAP EPS and $4.69 of adjusted EPS — and raised its full-year outlook for the second time this year.

The headline reads as a clean recovery quarter, and on the year-over-year comparison it is one: operating earnings rose 52% on flat revenue. The more useful question is what the numbers say about the rate of that recovery. Two details in the release answer it. The medical care ratio had help from reserve releases, and the raised full-year floor leaves relatively little for the fourth quarter.

UnitedHealth Q3 2026 results at a glance

	Q3 2026	Consensus	Q3 2025	Q2 2026
Revenue	$112,694M	~$111.3–111.4B	$113,161M	$112,032M
Earnings from operations	$6,563M	—	$4,315M	$7,991M
GAAP diluted EPS	$4.56	—	$2.59	$6.04
Adjusted EPS	$4.69	~$4.12–4.14	$2.92	$6.38
Medical care ratio	88.4%	—	89.9%	86.7%
Operating cost ratio	12.8%	—	13.5%	12.7%
Net margin	3.6%	—	2.1%	4.9%

Revenue fell 0.4% year over year and rose 0.6% sequentially. Earnings from operations rose 52% year over year, GAAP EPS 76% and adjusted EPS 61% (our arithmetic). Against the consensus figures reported by Zacks (via the Associated Press) and MarketBeat, adjusted EPS came in roughly 55 to 57 cents higher and revenue about $1.3–1.4 billion higher.

Cash flow from operations was $5.1 billion, or 1.2 times net earnings of $4,300 million; for the nine months it was $25,087 million against $18,589 million a year earlier. The debt-to-capital ratio was 41.7%, up from 41.2% at June 30, against the company’s target of about 40.0% by year-end.

Did UnitedHealth issue guidance for Q3 2026?

No — UnitedHealth Group does not issue quarterly revenue or earnings guidance; the outlook in its July 16, 2026 8-K covers full-year 2026 only. Against that outlook it raised its targets again, to at least $19.50 of GAAP EPS and at least $20.50 of adjusted EPS, from $18.45–$18.95 and $19.50–$20.00 (detail below). Against the year-ago quarter, revenue fell 0.4% to $112,694 million (our arithmetic), while GAAP diluted EPS rose to $4.56 from $2.59 and adjusted EPS to $4.69 from $2.92.

Where the margin came from: medical costs fell faster than premiums

Premium revenue was $87,078 million, down $1,901 million from $88,979 million a year ago. Medical costs fell further, to $76,982 million from $79,958 million — a decline of $2,976 million. That gap is the quarter. The medical care ratio (medical costs divided by premiums) dropped to 88.4% from 89.9%, and the release attributes the improvement to medical cost management, benefit design changes, pricing discipline and care-delivery changes.

Operating costs helped too. The operating cost ratio was 12.8% against 13.5% a year ago, with operating costs of $14,369 million against $15,223 million.

The $610 million inside the 88.4%

The release states that the medical care ratio “was impacted by $610 million of net favorable prior period reserve development related to 2026 dates of service.” In plain terms: claims incurred earlier in 2026 came in lower than the company had reserved for, and the release of that excess reduced medical costs recorded this quarter.

Two observations, both our arithmetic:

• Without the $610 million, the ratio would have been roughly 89.1%, not 88.4% — still better than the 89.9% of a year ago, but a smaller improvement (about 0.8 points rather than 1.5).
• Because it relates to 2026 dates of service, this is a shift between 2026 quarters, not a gift from prior years. It flatters the third quarter’s own ratio, but it does not add to the full-year total; it means the first half was better than first reported. The second quarter carried a similar item — $860 million of net favorable prior period development, “the majority related to 2026 dates of service,” according to the July release.

For scale, $610 million is about $0.68 per diluted share before tax on 902 million shares (our arithmetic; the company does not quantify a per-share effect). It is not excluded from adjusted EPS.

Reserve adequacy can also be read from the balance sheet. Days claims payable were 47.0, unchanged from the second quarter and up from 46.2 a year ago, and medical costs payable were $39,352 million against $39,337 million at December 31, 2025. On those measures the company released reserves without thinning the cushion.

Did UnitedHealth raise its 2026 guidance?

Yes, for the second time in 2026. The October release sets the full-year outlook at at least $19.50 of GAAP EPS and at least $20.50 of adjusted EPS, “incorporating experience through the third quarter.” The path so far, from the company’s releases:

2026 outlook	GAAP EPS	Adjusted EPS	Net earnings to shareholders
January 27, 2026	> $17.10	> $17.75	> $15,600M
July 16, 2026	$18.45–$18.95	$19.50–$20.00	> $16,750M
October 13, 2026	At least $19.50	At least $20.50	> $17,650M

The new adjusted floor is 50 cents above July’s top end and $2.75 above the January figure (our arithmetic). The October release gives the per-share and net-earnings figures only; it does not restate the July outlook’s medical care ratio (88.1% ± 25 bps), tax rate (18.5%), operating cash flow ($24.0 billion) or segment earnings.

The fourth-quarter arithmetic

Nine-month adjusted EPS is $18.30 and GAAP EPS is $17.50. Subtract those from the new floors and the outlook implies fourth-quarter adjusted EPS of roughly $2.20 or more and GAAP EPS of roughly $2.00 or more — set against $4.69 and $4.56 in the third quarter. In dollars, the net-earnings floor of more than $17,650 million less the nine-month $15,874 million leaves more than $1,776 million for the quarter, and the adjusted net-earnings floor of more than $18,585 million less the nine-month $16,598 million leaves more than $1,987 million (all our arithmetic). Because full-year EPS is calculated on full-year average shares, subtracting per-share figures is an approximation, not an exact quarterly guide.

“At least” is a floor, not a forecast, and the release does not say what it assumes for the fourth quarter.

There is also a tax wrinkle. The third-quarter tax provision of $1,224 million on $5,524 million of pre-tax earnings is an effective rate of about 22.2%, against roughly 19.6% for the nine months and the ~18.5% full-year rate in the July outlook (our arithmetic).

GAAP vs adjusted: the gap is small, and this quarter it runs both ways

UnitedHealth’s adjusted EPS of $4.69 is only 13 cents above GAAP EPS of $4.56. The reconciliation adds back $0.41 of intangible amortization but subtracts $0.16 of net gains from portfolio divestitures and South American impacts, $0.08 of restructuring and other items (including a $95 million decrease in loss contract reserves) and a $0.04 tax effect.

The same pattern shows up in operating earnings: adjusted earnings from operations were $6,265 million, about $298 million below the reported $6,563 million. This quarter the adjustments mostly remove gains rather than add back costs, so the adjusted figure is the more conservative of the two at the operating line.

Segments: Optum Health’s margin turnaround and a shrinking insurance book

Q3 2026	Revenue	YoY	Earnings from operations	Operating margin	Q3 2025 margin
UnitedHealthcare	$86,330M	-0.8%	$2,831M	3.3%	2.1%
Optum Health	$22,910M	-9.9%	$735M	3.2%	0.2%
Optum Insight	$5,474M	+2.9%	$1,279M	23.4%	17.3%
Optum Rx	$39,927M	+0.6%	$1,718M	4.3%	3.9%
Total Optum	$66,883M	-3.3%	$3,732M	5.6%	3.6%

Year-over-year percentage changes are our arithmetic; Optum figures include intersegment eliminations as the company presents them.

UnitedHealthcare earned $2,831 million against $1,805 million a year ago, with the margin up to 3.3% from 2.1%. Medicare & Retirement revenue fell to $42,420 million from $43,356 million; Employer & Individual rose to $20,208 million from $19,875 million; Community & State was $23,702 million against $23,839 million.

Optum Health is the sharpest swing. Revenue fell 10% to $22.9 billion, which the company attributes to “fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence,” yet earnings from operations rose to $735 million from $41 million. Part of that is non-recurring by the company’s own definitions: adjusted earnings from operations were $588 million, a 2.6% adjusted margin, after removing $85 million of net divestiture and South American impacts and $62 million of restructuring and other items.

Optum Insight posted a 23.4% margin on $5.5 billion of revenue, with earnings up to $1,279 million from $920 million. Optum Rx earned $1,718 million, up from $1,549 million, even as adjusted scripts fell to 393 million from 414 million, which the release ties to membership declines within UnitedHealthcare and other customers.

Optum supplied about 57% of consolidated earnings from operations this quarter (our arithmetic).

The membership trade-off

The margin repair has come with a smaller book. UnitedHealthcare served 48.3 million people at September 30, against 48.525 million at June 30 and 50.125 million a year earlier — about 1.8 million fewer (our arithmetic). By line, from the people-served table:

• Medicare Advantage: 7.605 million, against 8.435 million a year ago and 8.445 million at year-end 2025. The release separately says seniors served through Medicare Advantage, including programs serving complex populations included in Medicaid, have contracted by 935,000 since year-end 2025.
• Medicaid: 6.695 million, against 7.460 million a year ago; the release cites ongoing Medicaid eligibility changes.
• Commercial risk-based: 7.575 million, against 8.440 million a year ago, while fee-based commercial grew to 22.180 million from 21.490 million.

The release also reports that the 2027 Medicare Advantage Stars results put at least 69% of members in 4+ Star plans, which it calls in line with expectations.

The trade-off is visible in the income statement: revenue roughly flat, medical costs down, margins up. Whether that mix can grow again is a 2027 pricing and enrollment question that this release does not answer.

Capital return and balance sheet

Year to date, the company repurchased $5,031 million of stock and paid $6,170 million of dividends. Diluted weighted-average shares were 902 million against 908 million a year ago. Total debt (short-term borrowings and current maturities of $5,617 million plus long-term debt of $68,714 million) was about $74.3 billion, down from about $78.4 billion at December 31, 2025, and cash and short-term investments were $28,549 million (debt totals are our arithmetic).

What to watch in Q4

• The fourth-quarter medical care ratio. The floor leaves room for a much weaker quarter than the third; the actual fourth-quarter ratio is the clearest test of how much of 2026’s improvement is durable.
• Reserve development. After $860 million in the second quarter and $610 million in the third, any further favorable — or unfavorable — development will show whether reserving has settled.
• Whether the floor was conservative. The outlook is framed as “at least”; the full-year results will show how much room it held.
• Membership into 2027. Medicare Advantage and Medicaid enrollment, and the 2027 Stars results, set the base for next year’s revenue.
• Optum Health’s adjusted margin. The 2.6% adjusted figure, not the 3.2% reported one, is the cleaner read on the value-based care repair.

Quick answers

What was UnitedHealth’s Q3 2026 revenue?

$112.7 billion ($112,694 million), down 0.4% from $113,161 million in Q3 2025.

What was UnitedHealth’s Q3 2026 EPS?

GAAP diluted EPS was $4.56 (vs $2.59 a year ago) and adjusted EPS was $4.69 (vs $2.92).

Did UnitedHealth raise its 2026 guidance?

Yes. Full-year 2026 guidance is now at least $19.50 GAAP and at least $20.50 adjusted EPS, up from $18.45–$18.95 and $19.50–$20.00 in July.

What was UnitedHealth’s medical care ratio in Q3 2026?

88.4%, against 89.9% a year earlier, including $610 million of net favorable prior period reserve development related to 2026 dates of service.

---

Sources and method. Company figures — total revenues of $112,694 million against $113,161 million a year ago (and $112.0 billion in Q2 2026), premiums of $87,078 million against $88,979 million, medical costs of $76,982 million against $79,958 million, operating costs of $14,369 million against $15,223 million, earnings from operations of $6,563 million against $4,315 million (and $8.0 billion in Q2 2026), earnings before income taxes of $5,524 million, a $1,224 million tax provision, net earnings of $4,300 million, net earnings attributable to shareholders of $4,110 million, GAAP diluted EPS of $4.56 against $2.59 and adjusted EPS of $4.69 against $2.92 on 902 million diluted shares (908 million a year ago); nine-month tax provision of $4,004 million, pre-tax earnings of $20,455 million, net earnings to shareholders of $15,874 million, GAAP EPS of $17.50 and adjusted EPS of $18.30; the medical care ratio of 88.4% (89.9% a year ago) and the $610 million of net favorable prior period reserve development; the operating cost ratio of 12.8% (13.5%); net margin of 3.6% (2.1%; 4.9% in Q2 2026); days claims payable of 47.0 (47.0 in Q2 2026, 46.2 a year ago); operating cash flow of $5.1 billion, or 1.2 times net income, and nine-month operating cash flow of $25,087 million against $18,589 million; debt-to-capital of 41.7% (41.2% at June 30) and the ~40.0% target; year-to-date repurchases of $5,031 million and dividends of $6,170 million; balance-sheet figures at September 30, 2026 and December 31, 2025; the non-GAAP reconciliation (intangible amortization of $0.41, divestiture and South American impacts of $(0.16), restructuring and other of $(0.08) including the $95 million decrease in loss contract reserves, tax effect of $(0.04)); adjusted earnings from operations of $6,265 million; segment revenue, earnings and margins and the Optum Health adjustments; UnitedHealthcare sub-segment revenues; people-served and adjusted-script figures; the 2027 Stars statement; and the full-year outlook of at least $19.50 GAAP EPS, at least $20.50 adjusted EPS and net earnings to shareholders of more than $17,650 million (and adjusted net earnings of more than $18,585 million, against $16,598 million for the nine months) — are UnitedHealth Group’s own disclosures in Exhibit 99.1 to the Form 8-K filed 2026-10-13 for the quarter ended 2026-09-30, read directly from the filing on SEC EDGAR and linked above. Exhibit 99.2 in the same filing is a graphical version of the same release. The January and July 2026 outlooks, Q2 2026 revenue of $112,032 million and earnings from operations of $7,991 million, Q2 2026 EPS ($6.04 GAAP, $6.38 adjusted), the Q2 medical care ratio (86.7%) and operating cost ratio (12.7%), the $860 million of Q2 favorable development, and the July outlook’s medical care ratio, tax rate and cash-flow figures come from Exhibit 99.1 to the Form 8-K filed 2026-07-16. The quoted language on reserve development, Optum Health’s revenue decline and Medicare Advantage membership is from the releases.

Not company figures, and attributed accordingly: the consensus estimates of $4.12 adjusted EPS and $111.38 billion of revenue (Zacks survey, as reported by the Associated Press) and $4.14 and $111.31 billion (MarketBeat). Whether the quarter beat or missed the company’s own guidance is judged only against the year-ago quarter, because UnitedHealth Group issued no quarterly guidance; the full-year outlook change is measured against the Form 8-K filed 2026-07-16. This piece makes no claim about the share-price reaction.

Our arithmetic, labelled as such: the year-over-year and sequential growth rates; the ~89.1% medical care ratio before the $610 million of favorable development and the ~$0.68 per-share pre-tax size of that item; the implied fourth-quarter floors of roughly $2.20 adjusted EPS, roughly $2.00 GAAP EPS, more than $1,776 million of net earnings and more than $1,987 million of adjusted net earnings; the ~22.2% and ~19.6% effective tax rates; the guidance changes versus July and January; the $1,901 million decline in premiums and $2,976 million decline in medical costs; the segment growth rates; Optum’s ~57% share of earnings from operations; the ~1.8 million year-over-year decline in people served; and total debt of about $74.3 billion and $78.4 billion. These are approximations built on the disclosed figures, not reported numbers. The interpretation — that the third quarter’s ratio was flattered by in-year reserve releases and that the raised floor implies a much softer fourth quarter — is our analysis, not a company statement, and is not a forecast.

Related: Johnson & Johnson Q3 2026 for the pharmaceutical and medtech side of US healthcare; JPMorgan Chase Q3 2026, another early report of the Q3 2026 season; and Hims & Hers Q2 2026 for a different healthcare business model.

Tradune shows what you actually hold across every account, and whether a position has beaten a plain index fund since you bought it. Educational analysis, not investment advice.